Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Commonwealth Equity Services LLC

Commonwealth Equity Services LLC grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 20.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 236,577 shares of the company’s stock after purchasing an additional 40,524 shares during the period. Commonwealth Equity Services LLC’s holdings in Novo Nordisk A/S were worth $24,474,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. CNB Bank bought a new position in Novo Nordisk A/S during the 4th quarter worth $26,000. Pacific Center for Financial Services grew its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Valued Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Bell Investment Advisors Inc lifted its position in shares of Novo Nordisk A/S by 79.9% during the 3rd quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock worth $26,000 after purchasing an additional 127 shares during the last quarter. Finally, Tyler Stone Wealth Management lifted its stake in shares of Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock valued at $27,000 after buying an additional 146 shares during the period. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating for the company. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $123.05 on Monday. The stock has a fifty day simple moving average of $127.20 and a two-hundred day simple moving average of $113.10. The firm has a market cap of $552.19 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 1.93 and a beta of 0.43. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.